Bend Research, Inc.

Dow Global Technolgoies LLC

Capsugel Belgium Nv

Nutrition & Biosciences USA 4, Inc.

Miller, Warren Kenyon

Smithey, Daniel Tod

Frankamp, Benjamin Lee

Warren Kenyon Miller

Dwayne Thomas Friesen

Daniel Tod Smithey

Walter Christian Babcock

David Keith Lyon

Corey Bloom

David J Edlund

Ravi Mysore Shanker

William John Curatolo

Douglas Alan Lorenz

Michael Mark Morgen

David Thomas Vodak

Marshall David Crew

Daniel Elmont Dobry

Scott B McCray

Oliver Petermann

Matthias Sprehe

Michael Jon Gumkowski

Bruce M Johnson

William Brett Caldwell

Hassan Benameur

Ralph Tadday

Benjamin Lee Frankamp

Maryline Clauzel

David Kenneth Lyon

Jonathan Leonard Cape

Roger Benjamin Ruggeri

James Alan Schriver Nightingale

In a process for preparing an esterified cellulose ether a cellulose ether is esterified with (i) an aliphatic monocarboxylic acid anhydride or (ii) a dicarboxylic acid anhydride or (iii) a combination of an aliphatic monocarboxylic acid anhydride and a dicarboxylic acid anhydride in the presence of an alkali metal carboxylate and an aliphatic carboxylic acid, wherein the molar ratio [alkali metal carboxylate/anhydroglucose units of cellulose ether] is not more than [1.20/1] and the molar ratio [aliphatic carboxylic acid/anhydroglucose units of cellulose ether] is from [3.55/1] to [9.0/1].

Process of preparing an esterified cellulose ether in the presence of an alkali metal carboxylate and an aliphatic carboxylic acid

The present disclosure relates to compositions of an aqueous colloidal dispersion of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and methods for making such colloidal dispersions.

Colloidal dispersion comprising HPMCAS

Disclosed are compositions including a solid dispersion comprising a dispersion polymer, a basic low-water solubility active, and an anionic counterion, as well as methods of making and using the compositions.

Solid dispersions of low-water solubility actives

Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof.

Pharmaceutical compositions of dextran polymer derivatives

A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble polymer, and a resuspending material selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethylcellulose, and pharmaceutically acceptable salt forms thereof.

Pharmaceutical compositions comprising nanoparticles and a resuspending material

A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a non-ionizable cellulosic polymer, and TPGS.

Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate

Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.

Pharmaceutical compositions with enhanced performance

A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer.

Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer

Methods and compositions for maintaining an active agent in an intra-articular space are disclosed. Methods of delivering the compositions to an intra-articular space and methods of making the compositions also are disclosed. The compositions comprise an active agent and a polymer comprising at least one cationic group. A fluid including the composition may be injected into an intra-articular space in a human or animal whereby the composition associates with endogenous material in the intra-articular space. In some embodiments, the fluid further comprises a poorly aqueous soluble polymer.

Methods and compositions for maintaining active agents in intra-articular spaces

Solid dry powder compositions comprising active agents and dextran polymer derivatives comprising an ester-linked amine-containing substituent and an alkyl ester substituent are disclosed, as are methods for making such compositions.

Pharmaceutical compositions of active agents and cationic dextran polymer derivatives

Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility active agent and such polymers, the polymers provide increased aqueous concentrations and/or improved physical stability of the active agent.

Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution

A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.

Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer

Solid compositions of low-solubility drugs and poloxamers that provide concentration enhancement when administered to an aqueous environment of use are disclosed.

Solid compositions of low-solubility drugs and poloxamers

Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.

Growing community of inventors

Bend, OR, United States of America

Warren Kenyon Miller